Abstract: Drug formulations and methods for removing, reducing, or preventing the formation of fatty acid particles in drug formulations are provided. In particular, this disclosure sets forth the inclusion of human serum albumin in an active pharmaceutical agent formulation, such as an antibody drug formulation, at an effective concentration for reducing fatty acid particle formation and solubilizing fatty acid particles.

Abstract: Methods for producing high concentration protein formulations having high stability are provided. Assays for selecting proteins and formulation conditions that have high self-repulsive attributes are used as an early step in the manufacturing process. Specifically, a protein concentration-dependent self-interaction nanoparticle spectroscopy method is employed as a protein colloidal interaction assay.

Abstract: Methods for producing high concentration protein formulations having high stability are provided. Assays for selecting proteins and formulation conditions that have high self-repulsive attributes are used as an early step in the manufacturing process. Specifically, a protein concentration-dependent self-interaction nanoparticle spectroscopy method is employed as a protein colloidal interaction assay.

Abstract: A method of determining the effect of non-specific interactions in simulated in vivo conditions is presently disclosed. The method includes (a) contacting a solution comprising a biologically relevant molecular crowding agent and a target molecule with a biosensor, wherein the surface of the biosensor comprises a capture molecule that specifically binds the target molecule; (b) allowing the target molecule to bind to the capture molecule; and (c) determining an amount of the target molecule bound to capture molecule using biolayer interferometry.

Abstract: A method of determining the effect of non-specific interactions in simulated in vivo conditions is presently disclosed. The method includes (a) contacting a solution comprising a biologically relevant molecular crowding agent and a target molecule with a biosensor, wherein the surface of the biosensor comprises a capture molecule that specifically binds the target molecule; (b) allowing the target molecule to bind to the capture molecule; and (c) determining an amount of the target molecule bound to capture molecule using biolayer interferometry.

Abstract: A method of determining the effect of non-specific interactions in simulated in vivo conditions is presently disclosed. The method includes (a) contacting a solution comprising a biologically relevant molecular crowding agent and a target molecule with a biosensor, wherein the surface of the biosensor comprises a capture molecule that specifically binds the target molecule; (b) allowing the target molecule to bind to the capture molecule; and (c) determining an amount of the target molecule bound to capture molecule using biolayer interferometry.

Abstract: Methods for producing high concentration protein formulations having high stability are provided. Assays for selecting proteins and formulation conditions that have high self-repulsive attributes are used as an early step in the manufacturing process. Specifically, a protein concentration-dependent self-interaction nanoparticle spectroscopy method is employed as a protein colloidal interaction assay.

Abstract: Methods for producing high concentration protein formulations having high stability are provided. Assays for selecting proteins and formulation conditions that have high self-repulsive attributes are used as an early step in the manufacturing process. Specifically, a protein concentration-dependent self-interaction nanoparticle spectroscopy method is employed as a protein colloidal interaction assay.

Abstract: Drug formulations and methods for removing, reducing, or preventing the formation of fatty acid particles in drug formulations are provided.

Abstract: Drug formulations and methods for removing, reducing, or preventing the formation of fatty acid particles in drug formulations are provided.

Abstract: Drug formulations and methods for removing, reducing, or preventing the formation of fatty acid particles in drug formulations are provided.

Abstract: A method of determining the effect of non-specific interactions in simulated in vivo conditions is presently disclosed. The method includes (a) contacting a solution comprising a biologically relevant molecular crowding agent and a target molecule with a biosensor, wherein the surface of the biosensor comprises a capture molecule that specifically binds the target molecule; (b) allowing the target molecule to bind to the capture molecule; and (c) determining an amount of the target molecule bound to capture molecule using biolayer interferometry.

Abstract: Methods for producing high concentration protein formulations having high stability are provided. Assays for selecting proteins and formulation conditions that have high self-repulsive attributes are used as an early step in the manufacturing process. Specifically, a protein concentration-dependent self-interaction nanoparticle spectroscopy method is employed as a protein colloidal interaction assay.

Abstract: The present invention provides methods for the determination of the degree of molecular recognition of a protein with a ligand, including a first protein with a second protein. The methods may comprise determining the squared generalized order parameter (hereinafter, O) for at least one intramolecular bond of the first protein. The protein is then formed into a complex with a ligand. The value or values of O2 for the said at least one bond of the protein is then determined while the protein and the ligand are in the complex. The O value or values determined for the protein while the protein and the ligand are in a complex are compared or related to the O value or values determined for the uncomplexed protein.

Abstract: The present invention provides methods for the determination of the degree of molecular recognition of a protein with a ligand, including a first protein with a second protein. The methods may comprise determining the squared generalized order parameter (hereinafter, O) for at least one intramolecular bond of the first protein. The protein is then formed into a complex with a ligand. The value or values of O2 for the said at least one bond of the protein is then determined while the protein and the ligand are in the complex. The O value or values determined for the protein while the protein and the ligand are in a complex are compared or related to the O value or values determined for the uncomplexed protein.

Abstract: A method and system for real estate transactions concerning the purchase or sale of real property is provided.